Results 21 to 30 of about 166,355 (310)

Identification of EMP1 as a critical gene for cisplatin resistance in ovarian cancer by using integrated bioinformatics analysis

Cancer Medicine, 2023
Background Cisplatin resistance is among the main reasons for the poor prognosis of ovarian cancer (OC) patients. Until now, effective biomarkers for predicting cisplatin resistance in OC and specific drugs for reversing this resistance are lacking. This
Qingsong Zeng, Cunjian Yi, Jinzhi Lu, Xiaowen Wang, Keming Chen, Li Hong   +5 more
doaj   +1 more source

A novel CREB5/TOP1MT axis confers cisplatin resistance through inhibiting mitochondrial apoptosis in head and neck squamous cell carcinoma

BMC Medicine, 2022
Background Cisplatin resistance is one of the main causes of treatment failure and death in head and neck squamous cell carcinoma (HNSCC). A more comprehensive understanding of the cisplatin resistance mechanism and the development of effective treatment
Tong Tong, Xing Qin, Yingying Jiang, Haiyan Guo, Xiaoning Wang, Yan Li, Fei Xie, Hao Lu, Peisong Zhai, Hailong Ma, Jianjun Zhang   +10 more
doaj   +1 more source

FAM83B inhibits ovarian cancer cisplatin resistance through inhibiting Wnt pathway

Oncogenesis, 2021
Cisplatin resistance is frequently occurred in ovarian cancer therapy, understanding its regulatory mechanisms is critical for developing novel treatment methods and drugs.
Shanyang He, Wei Wang, Zhiyong Wan, Hongwei Shen, Yunhe Zhao, Zeshan You, Jun Liu, Liwen Zhu   +7 more
doaj   +1 more source

The Role of Tumour Metabolism in Cisplatin Resistance

Frontiers in Molecular Biosciences, 2021
Cisplatin is a chemotherapy drug commonly used in cancer treatment. Tumour cells are more sensitive to cisplatin than normal cells. Cisplatin exerts an antitumour effect by interfering with DNA replication and transcription processes.
Lude Wang, Xiaoya Zhao, Jianfei Fu, Wenxia Xu, Jianlie Yuan   +4 more
doaj   +1 more source

Mitochondrial Involvement in Cisplatin Resistance [PDF]

International Journal of Molecular Sciences, 2019
Cisplatin is one of the worldwide anticancer drugs and, despite its toxicity and frequent recurrence of resistance phenomena, it still remains the only therapeutic option for several tumors. Circumventing cisplatin resistance remains, therefore, a major goal for clinical therapy and represents a challenge for scientific research.
Veronica Cocetta, Eugenio Ragazzi, Monica Montopoli   +2 more
openaire   +3 more sources

Eukaryotic initiation factor 5A2 mediates hypoxia-induced autophagy and cisplatin resistance

Cell Death and Disease, 2022
Hypoxia-induced cisplatin resistance is a major challenge during non-small cell lung cancer (NSCLC) treatment. Based on previous studies, we further explored the effect of eukaryotic initiation factor 5A2 (eIF5A2) in hypoxia-induced cisplatin resistance.
Guodong Xu, Hang Chen, Shibo Wu, Jiabin Chen, Shufen Zhang, Guofeng Shao, Lebo Sun, Yinyu Mu, Kaitai Liu, Qiaoling Pan, Ni Li, Xiaoxia An, Shuang Lin, Wei Chen   +13 more
doaj   +1 more source

Molecular mechanisms of cisplatin resistance [PDF]

Oncogene, 2011
Platinum-based drugs, and in particular cis-diamminedichloroplatinum(II) (best known as cisplatin), are employed for the treatment of a wide array of solid malignancies, including testicular, ovarian, head and neck, colorectal, bladder and lung cancers.
L, Galluzzi, L, Senovilla, I, Vitale, J, Michels, I, Martins, O, Kepp, M, Castedo, G, Kroemer   +7 more
openaire   +2 more sources

Cemiplimab for Cisplatin Resistant Metastatic Penile Cancer [PDF]

Case Reports in Oncology, 2021
We report on a 75-year old man who presented with metastatic, squamous-cell carcinoma (SCC) of the penis whose disease had progressed after radiotherapy (RT) and cisplatin-based chemotherapy (CT). A strong PD-L1 expression as well as a CDKN2A mutation was documented, and he was given cemiplimab every 3 weeks at time of disease progression.
Denis, Chloé, Sakalihasan, Sarah, FRERES, Pierre, WITHOFS, Nadia, SAUTOIS, Brieuc   +4 more
openaire   +3 more sources

Cisplatin induces resistance by triggering differentiation of testicular embryonal carcinoma cells. [PDF]

PLoS ONE, 2014
Although testicular germ cell tumors are generally quite responsive to treatment with cisplatin, a small fraction of them acquire resistance during therapy. Even when cisplatin treatment is successful the patient is often left with a residual teratoma at
Paolo B Abada, Stephen B Howell
doaj   +1 more source

Oxaliplatin induces drug resistance more rapidly than cisplatin in H69 small cell lung cancer cells [PDF]

, 2006
Cisplatin produces good responses in solid tumours including small cell lung cancer (SCLC) but this is limited by the development of resistance. Oxaliplatin is reported to show activity against some cisplatin-resistant cancers but there is little known ...
A Ibrahim, A Rennicke, AB Sandler, AP Jekunen, BA Jansen, BA Teicher, Britta K. Stordal, BS Burns, C Kollmannsberger, C Kollmannsberger, CR Culy, D Pectasides, D Pectasides, DC Marks, G Belvedere, G Lenz, G Tisman, GA Hospers, H Kawai, H Kuroda, HD Preisler, HD Preisler, IS Song, J Liu, JM Woynarowski, JM Woynarowski, K Suzukake, K Yamamoto, KV Grech, L Pendyala, L Poulain, M Abal, M Markman, M Mishima, Mary W. Davey, N Jain, N Savaraj, N Thatcher, O Rixe, P Chollet, P Soulie, PJ Kuppen, PR Twentyman, R Sockalingam, RD Christen, Ross A. Davey, S Hector, S Ohta, SG Chaney, SL Lai, SW Johnson, T Fojo, T Moritaka, T Tashiro, V Dieras, VL Locke, WS Hong, Z El Akawi, Z Wang   +58 more
core   +2 more sources